Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication (original) (raw)
Related papers
Radio-iodine Therapy in Hyperthyroidism- A Study of 50 Cases
Journal of Medicine, 2008
The use of radioiodine-131 for the treatment of hyperthyroidism is a very simple and cheap form of therapy and highly effective and is now the predominant definitive therapy both as primary treatment and following relapse after anti thyroid drugs. This study was carried out in Khulna medical college from January 2002 to January 2003 to assess the degree of effectiveness of radioiodine therapy in case of hyperthyroidism. This was a prospective study of 50 patients with hyperthyroidism (28 female, 22 male, mean age 39.87 years) treated with radioiodine-131 and followed up for a period of one year. The dose of radioiodine-131 ranged from 7-10 mci. Out of 50 patients 38 (76%) were found to have diffuse toxic goitre, 5(10%) have solitary toxic nodule 1(2%) have multi nodular toxic goitre, 4(8%) have impalpable gland with thyrotoxicosis and 2(4%) with relapsing thyrotoxicosis received oral radioiodine therapy. Serum T3 was elevated in 43(86%) and was normal in 7(14%) cases. Serum T4 was n...
Annals of Nuclear Medicine, 2005
The purpose of this retrospective study was to evaluate the incidence of recurrence and the success of radioiodine treatment (RIT) in the Trakya region of Turkey, an area with mild iodine deficiency, and to compare the effect of dose regimen selection (fixed (FD) or calculated dose (CD)) on treatment success. Material and Methods: The study sample included 148 patients (40 male, median age 50) treated with radioiodine between the years 1991-2003. Patients were categorized into three diagnostic groups: Graves' disease (GD) (n = 65), solitary toxic adenoma (TA) (n = 29), and toxic multinodular hyperthyroidism (TMH) (n = 54), and each divided into two subgroups according to treatment method; the first group was treated with a FD of 370 MBq (10 mCi), and the second with CD. Results: The largest group was GD (44%), followed by TMH (36%). Median duration of follow-up was 28 months (range 6-147). FD was given to 52.7% of all patients and CD was given to 47.3%. There was a partial difference in the dose regimen between all groups, but did not reach statistically significant levels (FD vs. CD: 65%-35%; 38%-62%; 46%-54%; GD, TA, TMH respectively, p > 0.05). Total cure rate in FD and CD was 46 (59%) and 37 (52.9%), respectively. The rates of hypothyroidism for GD, TA, and TMH groups were 28 (43.1%), 6 (20.7%) and 16 (29.6%), respectively. The incidence of hypothyroidism did not vary significantly between any groups (p > 0.05). At the end of the follow-up period, a total of 104 patients (70.3%) were treated successfully. There was no significant difference in the cure rate between any groups (p > 0.05). Conclusions: The treatment success in all groups and subgroups did not differ significantly between FD and CD. Our lower cure rate than in previous studies may be related to iodine deficiency. Higher doses of radioiodine may be required to increase final treatment success in endemic goiter areas. If this true, dosimetry and calculated dose regimen would be required in all groups of patients instead of an FD concept. However, our findings should be verified in larger series of patients, with longer follow-up period, and urinary iodine concentration measurements.
Radioiodine Therapy Outcome in Patients with Hyperthyroidism in A Tertiary Care Centre
2012
The purpose of the retrospective study was to assess the outcome of radioiodine therapy in patients treated for thyrotoxicosis. Material and Methods : The medical records of 64 patients (age between 23 and 56 years). These hyperthyroid patients were treated with radioiodine and we have one year follow-up in these patients. Parameters for analysis included the age, sex, clinical symptoms, type of hyperthyroidism, anti-thyroid medications received by the subjects, doses of radioiodine therapy given and the outcome of the therapy after one year. Results : Of all the patients 80% of them were females. The most common cause of hyperthyroidism was Graves' disease (77%) followed by toxic single and/or multinodular goitres (23%). All patients were pre-treated with carbimazole for variable duration. The patients were treated with fixed dose of 131-Iodine toxic therapy with mean administered dose of radioiodine was 8.0 ± 0.5 mCi. Effective control of hyperthyroidism with a single dose of ...
Cureus
Background Radioactive iodine (RAI) is the treatment of choice for most patients with primary hyperthyroidism. The most common etiologies of hyperthyroidism are Graves' disease (GD), toxic adenoma (TA), and toxic multinodular goiter (TMNG). A single dose of RAI is usually sufficient to cure hyperthyroidism. The aim of this study was to assess the effectiveness of RAI therapy for patients diagnosed with primary hyperthyroidism. Methods and materials Patients diagnosed with hyperthyroidism who received RAI therapy between 2008 and 2018 were included in the study. The data was acquired from the hospital's electronic medical record system. Following the RAI treatment, a cure was defined as the development of euthyroidism or hypothyroidism after a single fixeddose without antithyroid medication within one year of RAI therapy. In addition, a simple logistics regression model was used to identify the prognostic factors that may lead to better outcomes. Results A total of 112 patients diagnosed with hyperthyroidism with a mean age of 47 ± 14 were included in this study. The majority of the patients were female, 79 (70.5%). Within one year of RAI therapy, 84 (75%) patients achieved a cure that is either hypothyroid or euthyroid status. RAI dose was higher in responsive patients (18.50 ± 4.10 millicurie [mCi] versus 16.50 ± 4.10 mCi) than in non-responsive patients. The mean RAI doses were 16.05 ± 2.99 mCi in GD, 19.81 ± 4.40 mCi in TMNG, and 20.50 ± 3.30 mCi in TA, with a statistically significant p-value of 0.001. In the univariable logistic regression model, RAI dose was a significant prognostic factor of the responsive group (OR: 1.15, CI [1.01-1.31], p-value 0.03). Conclusion Our data presented that RAI therapy is effective for primary hyperthyroidism. We achieved remission with a single fixed-dose in the majority of patients. Most of our patients were cured within three months of RAI therapy. In addition, the RAI dose was higher in the responsive group as compared to the non-responsive group.
Thyroglobulin as a possible predictor of doses radioiodine therapy in hyperthyroidism
Acta Medica Saliniana, 2018
Introduction According to guidelines for the management of hyperthyroidism, patients with hyperthyroidism should be treated with radioactive iodine, antithyroid drugs, or thyroidectomy. Oral administration of radioiodine is a safe and cost effective treatment option for patients with toxic multinodular goiter (TMG)/toxic adenoma (TA) or Grave’s disease (GD). The aim of the study was to evaluate the use of thyroglobulin values as a possible predictor of a dose of radioiodine therapy (RAI) in hyperthyroidism in patients GD, TA and TMG. Results The study included 105 patients (14.4 % males and 85.6% females). The average duration of the disease was 9 years. Graves’s disease is registered among 50.68%, toxic multinodular goiter among 30.83% and toxic adenoma among 18.49% of patients. Patients were divided into four groups, and they received four doses of radioiodine therapy: 10mCi, 15mCi, 20mCi and 25mCi. The values of thyroglubulin were measured before RAI, and in period of one, three ...
Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine, 2009
To evaluate the efficacy of a fixed dose of radioactive iodine (131-I) in the treatment of thyrotoxicosis, and to identify risk factors associated with treatment failure. Retrospective study. Thyroid Clinic of a regional hospital in Hong Kong. Patients receiving their first dose of radioactive iodine for the treatment of thyrotoxicosis during the inclusive period September 1999 to August 2004. Relapse rate and time to relapse. A total of 113 patients received a fixed dose of 5 mCi (185 MBq), 6 mCi (222 MBq), 8 mCi (296 MBq), and 10 mCi (370 MBq) 131-I in a proportion of 1:6:71:35. At 1 year, 42 (37%) of the patients had relapsed, of which 69% received a second 131-I dose. The median time to relapse after first receiving 131-I was 4 months. At 1 year, the remaining 71 (63%) of the patients were successfully treated; 46 (41%) were euthyroid, and 25 (22%) had became permanently hypothyroid. Basal free thyroxine level and goitre size were significantly associated with a relapse rate aft...
Efficacy of radioiodine in the treatment of primary hyperthyroidism
Ibnosina Journal of Medicine and Biomedical Sciences
Background: Radioiodine (RI) is a commonly used treatment modality for primary hyperthyroidism. A single dose of RI has been reported to cure hyperthyroidism in the range of 50%–90% of the treated cases. The efficacy of RI treatment has not yet been investigated in the local population. Objectives: To assess the efficacy of RI therapy in patients with primary hyperthyroidism treated at Tawam Hospital, Al Ain, UAE. Patients and Methods: The electronic medical records of hyperthyroid patients who received RI treatment at Tawam Hospital between January 2009 and March 2017 were reviewed. The diagnosis was verified by reviewing clinical, laboratory, and imaging data. Following RI therapy, a cure was defined as the development of hypothyroidism or euthyroid status without the aid of antithyroid drugs (ATDs) within 6 months post-RI therapy. Multivariate analysis was used to assess predictors of RI response. Results: A total of 125 patients (68.8% women) met the study criteria. The mean age...